Item 2.02 Results of Operations and Financial Condition. On November 13, 2026, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the three and nine months ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this Current Report on Form 8-K.…
Filed Nov 13, 2026Accepted Nov 13, 2026, 8:10 AM ESTCIK 1858685Accession 0001493152-26-051546
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 2.02Item 2.02 - Results of Operations
Item
2.02 Results of Operations and Financial Condition.
On
November 13, 2026, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results
for the three and nine months ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 attached hereto
to this Current Report on Form 8-K.
The
Company’s press release contains non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of
a company’s performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded
or included in the most directly comparable measure calculated and presented in accordance with United States generally accepted accounting
principles, or GAAP. Pursuant to the requirements of Regulation G, the Company has provided within the press release quantitative reconciliations
of the non-GAAP financial measures to the most directly comparable GAAP financial measures.
The
information contained in this Item 2.02 in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference
in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm
Exhibit
99.1
Biofrontera
Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth
WOBURN,
Mass., November 13, 2026 - Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical
company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial
results for the quarter ended September 30, 2026.
Third
Quarter 2026 Highlights
Net
product revenue of $9.1 million, an increase of 29.8% compared to $7.0 million in the prior-year
period.
Gross
margin of 74.4%, compared to 70.7% in the prior-year period, an improvement of approximately
370 basis points, reflecting the lower Ameluz® cost structure established
following the closing of the strategic transaction with Biofrontera AG in October 2025 (the
“Strategic Transaction”), partially offset by ITC Matter-related inventory write-downs
and higher lamp and device costs.
Net
loss of $6.4 million, or $(0.42) per share, compared to a net loss of $6.6 million, or $(0.62)
per share, in the prior-year period.
Adjusted
EBITDA of $(5.5) million, compared to $(6.0) million in the prior-ye…